Avadel Pharmaceuticals Enters Material Agreement
| Field | Detail |
|---|---|
| Company | Avadel Pharmaceuticals PLC |
| Form Type | 8-K |
| Filed Date | Oct 22, 2025 |
| Risk Level | medium |
| Pages | 5 |
| Reading Time | 6 min |
| Key Dollar Amounts | $0.01, $90 million |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-agreement, disclosure, exhibits
TL;DR
Avadel Pharma inked a new deal, filing an 8-K. Big moves ahead.
AI Summary
On October 21, 2025, Avadel Pharmaceuticals plc entered into a material definitive agreement. The company also made a Regulation FD disclosure and filed financial statements and exhibits. Avadel Pharmaceuticals plc is incorporated in Ireland and its principal executive offices are located in Dublin.
Why It Matters
This filing indicates a significant new development for Avadel Pharmaceuticals, potentially impacting its business operations and financial standing.
Risk Assessment
Risk Level: medium — Material definitive agreements can introduce new risks or opportunities, the specifics of which are not detailed in this initial filing.
Key Players & Entities
- AVADEL PHARMACEUTICALS PLC (company) — Registrant
- October 21, 2025 (date) — Date of earliest event reported
- Ireland (location) — State or other jurisdiction of incorporation
- Dublin 2 (location) — Principal executive offices
FAQ
What is the nature of the material definitive agreement entered into by Avadel Pharmaceuticals?
The filing does not specify the nature of the material definitive agreement, only that one was entered into on October 21, 2025.
What is the exact date of the earliest event reported in this 8-K filing?
The earliest event reported is dated October 21, 2025.
Where are Avadel Pharmaceuticals plc's principal executive offices located?
Avadel Pharmaceuticals plc's principal executive offices are located at 10 Earlsfort Terrace, Dublin 2, Ireland.
What is the Commission File Number for Avadel Pharmaceuticals plc?
The Commission File Number for Avadel Pharmaceuticals plc is 001-37977.
What are the key items reported in this 8-K filing?
This 8-K filing reports an entry into a material definitive agreement, a Regulation FD disclosure, and financial statements and exhibits.
Filing Stats: 1,456 words · 6 min read · ~5 pages · Grade level 11.1 · Accepted 2025-10-22 06:40:18
Key Financial Figures
- $0.01 — stered Ordinary Shares, nominal value $0.01 per share AVDL The Nasdaq Global Ma
- $90 million — other things, (i) a payment by Jazz of $90 million (the "Settlement Payment") to Avadel CN
Filing Documents
- tm2529228d1_8k.htm (8-K) — 35KB
- tm2529228d1_ex99-1.htm (EX-99.1) — 28KB
- 0001104659-25-101382.txt ( ) — 234KB
- avdl-20251021.xsd (EX-101.SCH) — 3KB
- avdl-20251021_lab.xml (EX-101.LAB) — 33KB
- avdl-20251021_pre.xml (EX-101.PRE) — 22KB
- tm2529228d1_8k_htm.xml (XML) — 3KB
01
Item 1.01 Entry into a Material Definitive Agreement. On October 21, 2025, Avadel CNS Pharmaceuticals, LLC ("Avadel CNS"), a subsidiary of Avadel Pharmaceuticals plc (the "Company" or "Avadel"), entered into a Settlement and License Agreement (the "Settlement Agreement") with Jazz Pharmaceuticals, Inc. ("Jazz") to resolve the previously disclosed actions captioned Jazz Pharmaceuticals, Inc. v. Avadel CNS Pharmaceuticals, LLC , C.A. No. 21-691; Jazz Pharmaceuticals, Inc. et al v. Avadel CNS Pharmaceuticals, LLC , C.A. No. 21-1138; Jazz Pharmaceuticals, Inc. et al v. Avadel CNS Pharmaceuticals, LLC , C.A. No. 21-1594; Avadel CNS Pharmaceuticals, LLC et al v. Jazz Pharmaceuticals, Inc. et al , C.A. No. 22-487; Avadel CNS Pharmaceuticals, LLC v. Jazz Pharmaceuticals, Inc. , C.A. No. 22-941; Avadel CNS Pharmaceuticals, LLC et al v. Jazz Pharmaceuticals, Inc., et al , C.A. No. 25-09; Avadel CNS Pharmaceuticals, LLC et al v. Jazz Pharmaceuticals, Inc. et al , C.A. No. 25-57; Avadel CNS Pharmaceuticals, LLC et al v. Jazz Pharmaceuticals, Inc., et al , C.A. No. 25-221; and Avadel CNS Pharmaceuticals, LLC et al v. Jazz Pharmaceuticals, Inc. et al , C.A. No. 25-435, each brought in the United States District Court for the District of Delaware (collectively the "Lawsuits"). For additional information about the Lawsuits, see the Company's Quarterly Report on Form 10-Q for the quarter ended June 30, 2025, filed with the Securities and Exchange Commission on August 7, 2025 and the Company's Current Report on Form 8-K filed with the SEC on September 17, 2025. The Settlement Agreement provides for, among other things, (i) a payment by Jazz of $90 million (the "Settlement Payment") to Avadel CNS and a waiver by Jazz of its right to receive royalties and/or damages on sales of LUMRYZ through September 30, 2025; (ii) subject to and contingent upon payment of the Settlement Payment, each of Avadel CNS and Jazz agreed to dismiss their respective Lawsuits with prejudice; (iii) the pa
01. Regulation FD Disclosure
Item 7.01. Regulation FD Disclosure. On October 22, 2025, the Company issued a press release entitled "Avadel Pharmaceuticals and Jazz Pharmaceuticals Reach Global Settlement." A copy of the press release is furnished as Exhibit 99.1 to this Current Report on the Form 8-K. The information in this Item 7.01, including Exhibit 99.1 attached hereto, is intended to be furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.
01
Item 9.01. Exhibits (d) Exhibits 99.1 Press release issued by Avadel Pharmaceuticals plc on October 22, 2025. 104 Cover Page Interactive Data File (embedded with the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: October 22, 2025 AVADEL PHARMACEUTICALS PLC By: /s/ Jerad G. Seurer Name: Jerad G. Seurer Title: General Counsel & Corporate Secretary